Systematic review of oral carbohydrate treatment for hypoglycemia in people living with type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; 39 of the 68 sources its claims cite were checked for support.
Abstract
BACKGROUND: The common recommendation for hypoglycemia treatment, oral ingestion of 15 g of simple carbohydrates and glucose recheck in 15 min, was predominantly based on expert opinion, and two small-sized studies of intravenous insulin-induced hypoglycemia in people living with type 1 diabetes mellitus (T1D). The evidence for "15 grams/15 minutes" treatment for people living with type 2 diabetes mellitus (T2D) needs to be explored. The objective of this systematic review is to determine which oral carbohydrate treatments were studied in adults living with T2D for timely resolution of hypoglycemia events. METHODS: Medline, Embase, Scopus, and Cochrane Central Register of Controlled Trials were searched from January 1990 to 24 March 2025, for full-text studies of oral treatment for hypoglycemia in T2D. Two authors screened the results and extracted data. Inclusion criteria included age > = 18 years with T2D, treated with a defined quantity of simple carbohydrates, and reported hypoglycemia event resolution as a defined time of first glucose recheck after treatment completion. Exclusion criteria included non-oral route of hypoglycemia treatment. The Newcastle-Ottawa scale was used for risk of bias assessment. RESULTS: Three studies were included, which reported on 152 insulin-treated adults who experienced 366 hypoglycemia events. None of these three studies presented if the participants were or were not on sulfonylurea concurrently, nor did they present a breakdown of the types of insulin(s) (long-acting versus rapid-acting) for the participants. All studies had different oral hypoglycemia treatments and various glucose recheck times. Hence, data synthesis was not possible. There was near 100% hypoglycemia resolution with 15 g carbohydrates at 30-minute recheck in a study of mild hypoglycemia in hospitalized people living with type 2 diabetes. An at-home study showed 95% hypoglycemia resolution with 30 g carbohydrates at 10-minute recheck, although rebound hyperglycemia became a concern. The studies had low risk of bias. CONCLUSION: Three studies provided a very limited evidence base for hypoglycemia treatment in T2D. Future studies are encouraged to identify and analyze people living with T2D who are treated with sulfonylurea, with or without insulin therapy, to reflect hypoglycemia treatment over the breadth of T2D pharmacotherapy. CLINICAL TRIAL NUMBER: Not applicable. TRIAL REGISTRATION: Prospero registration number CRD420251032322. No amendments. Study protocol can be obtained by sending a written request to the corresponding author.
Overview
CoChat Summary
## TL;DR
This systematic review found only 3 small studies on oral carbohydrate treatment for hypoglycemia in adults with type 2 diabetes, covering 152 insulin-treated adults and 366 hypoglycemia events. The evidence base was too limited and heterogeneous to support a firm “15 g / 15 min” recommendation for T2D.
## Key findings
- 3 studies met inclusion criteria; together they reported 152 insulin-treated adults and 366 hypoglycemia events.
- The studies used different carbohydrate sources/amounts and different glucose recheck times, so data synthesis was not possible.
- One inpatient T2D study found near 100% hypoglycemia resolution with 15 g carbohydrates at 30 minutes; an at-home study found 95% resolution with 30 g carbohydrates at 10 minutes.
- The at-home study also reported rebound hyperglycemia in 62% and 63% of events treated with 30 g carbohydrates and 0.3 g/kg, respectively, using a rebound threshold of ≥ 8 mmol/L.
## Methods
- Design: Systematic review, registered on PROSPERO (CRD420251032322), searching MEDLINE, Embase, Scopus, and Cochrane Central from January 1990 to 24 March 2025.
- Sample/data: Included full-text English or French studies of adults (≥18 years) with T2D given a defined quantity of simple carbohydrates for hypoglycemia; non-oral treatment was excluded.
- Analysis: Two authors independently screened/extracted data and assessed risk of bias with the Newcastle-Ottawa scale; synthesis was only planned when studies matched on carbohydrate type/amount and recheck time, but this was not achievable.
## Limitations
- The paper states that the evidence was very limited, with only 3 small-sized studies; one study did not distinguish T2D from T1D, limiting certainty.
- The studies did not report whether participants were taking sulfonylureas or provide a breakdown of long-acting vs rapid-acting insulin.
- Evidence from one study was of limited applicability because it used a very low hypoglycemia resolution threshold (<3.5 mmol/L), which the authors note is below common guideline thresholds of 3.9 or 4.0 mmol/L.
- Evident from the text: the review searched only English/French full texts and published literature, so it may have missed abstract-only, non-English, or unpublished studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
23 Valid · 0 Not valid · 5 Not checked · 26 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Amongst the pharmacotherapies for people living with type 2 diabetes mellitus (T2D), insulin and sulfonylurea classes of medications are often associated with hypoglycemia [1].”
§ Systematic review of oral carbohydrate treatment for hypoglycemia in people living with type 2 diabetes mellitus > Introduction
What the sources say
- Supportedcites [1] Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care. 2005;28(12):2948–2961. https://doi.org/10.2337/diacare.28.12.2948 . PMID: 16306561. source
The “Epidemiological data from interventional trials” section reports hypoglycemia with both sulfonylurea and insulin treatment in people with type 2 diabetes. The observational-studies section likewise reports hypoglycemia among patients receiving each treatment class. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The majority of non-severe hypoglycemia events are treated by the person living with diabetes with oral ingestion of simple carbohydrates to rapidly raise the blood glucose levels [3–5].”
§ Systematic review of oral carbohydrate treatment for hypoglycemia in people living with type 2 diabetes mellitus > Introduction
What the sources say
- Not checked yetcites [3] Joint British Diabetes Societies for Inpatient Care. The hospital management of hypoglycaemia in adults with diabetes mellitus: JBDS-01 guideline January 2023. Available from: https://www.diabetes.org.uk/for-professionals/improving-care/good-practice/inpatient-and-hospital-care/joint-british-diabetes-society-for-inpatient-care
- Partly supportedcites [4] American Diabetes Association Professional Practice Committee. Glycemic goals and hypoglycemia: Standards of care in diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S128–S145. https://doi.org/10.2337/dc25-S006 . PMID: 39651981; PMCID: PMC11635034. sourceExperimental — accuracy not yet measured
The Hypoglycemia Treatment section recommends that individuals treat hypoglycemia with fast-acting carbohydrates and says glucose-containing carbohydrates raise blood glucose. The Hypoglycemia Definitions and Event Rates section says level 1 and 2 events make up the vast majority of hypoglycemic events. Neither section establishes that the majority of non-severe events are actually self-treated with oral carbohydrates; the treatment passage gives a recommendation, not an observed rate. (LLM, conf=0.86)
- Partly supportedcites [5] Lega IC, Yale JF, Chadha A, Paty B, Roscoe R, Snider M, Steier J, et al. Diabetes Canada 2023 update clinical practice guidelines for the prevention and management of diabetes in Canada: hypoglycemia in adults. Can J Diabetes. 2023;47(7):548–559. https://guidelines.diabetes.ca/cpg/chapter-14-2023-update sourceExperimental — accuracy not yet measured
The “Level 1 or 2 hypoglycemia” section says these events are self-treatable and that oral glucose raises blood glucose within 20 minutes. The treatment recommendations advise people with level 1 or 2 hypoglycemia to ingest fast-acting carbohydrate. The paper does not establish that a majority of non-severe events are actually treated this way; page numbers were not available in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A longer duration of type 2 diabetes is associated with a diminished counter-regulatory response to hypoglycemia [1, 17–21].”
§ Systematic review of oral carbohydrate treatment for hypoglycemia in people living with type 2 diabetes mellitus > Discussion > Limitations
What the sources say
- Partly supportedcites [1] Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care. 2005;28(12):2948–2961. https://doi.org/10.2337/diacare.28.12.2948 . PMID: 16306561. sourceExperimental — accuracy not yet measured
In the section on responses to hypoglycemia in type 2 diabetes (page unavailable), the review reports an almost absent glucagon response in insulin-deficient patients, supporting a diminished response in a subgroup. It does not establish that longer duration of type 2 diabetes is associated with that diminution; its explicit statement that a response declines with time concerns type 1 diabetes. (LLM, conf=0.84)
- Partly supportedcites [17] Ibrahim M, Baker J, Cahn A, Eckel RH, El Sayed NA, Fischl AH, Gaede P, Leslie RD, Pieralice S, Tuccinardi D, Pozzilli P, Richelsen B, Roitman E, Standl E, Toledano Y, Tuomilehto J, Weber SL, Umpierrez GE. Hypoglycaemia and its management in primary care setting. Diabetes Metab Res Rev. 2020;36(8):e3332. https://doi.org/10.1002/dmrr.3332. Epub 2020 May 18. PMID: 32343474. sourceExperimental — accuracy not yet measured
The section “Impaired Awareness of Hypoglycemia” reports that glucose counterregulation, mainly the glucagon response, was virtually absent in people with longstanding, insulin-treated type 2 diabetes. This supports the link with long disease duration, but the cited finding is limited to insulin-treated patients; the claim does not retain that qualifier. (LLM, conf=0.84)
- Not checked yetcites [18] Dhatariya K, Corsino L, Umpierrez GE. Management of diabetes and hyperglycemia in hospitalized patients. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000‑. Updated 30 Dec 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279093/
- Not checked — no full text of the sourcecites [19] Caruso I, Marrano N, Biondi G, Genchi VA, D’Oria R, Sorice GP, Perrini S, Cignarelli A, Natalicchio A, Laviola L, Giorgino F. Glucagon in type 2 diabetes: friend or foe? Diabetes Metab Res Rev. 2023;39(3):e3609. https://doi.org/10.1002/dmrr.3609. Epub 2023 Jan 30. PMID: 36637256. source
- Partly supportedcites [20] Hædersdal S, Lund A, Knop FK, Vilsbøll T. The role of glucagon in the pathophysiology and treatment of type 2 diabetes. Mayo Clin Proc. 2018;93(2):217–239. https://doi.org/10.1016/j.mayocp.2017.12.003 . Epub 2018 Jan 5. PMID: 29307553. sourceExperimental — accuracy not yet measured
The DPP-4is section states that the normal counter-regulatory response to hypoglycemia is impaired in patients with type 2 diabetes. It does not say that the impairment increases with longer diabetes duration; searches for duration and long-standing diabetes did not establish that association. The indexed passages provide no page numbers. (LLM, conf=0.86)
- Partly supportedcites [21] Wewer Albrechtsen NJ, Holst JJ, Cherrington AD, Finan B, Gluud LL, Dean ED, Campbell JE, Bloom SR, Tan TM, Knop FK, Müller TD. 100 years of glucagon and 100 more. Diabetologia. 2023;66(8):1378–94. https://doi.org/10.1007/s00125-023-05947-y. Epub 2023 Jun 27. PMID: 37367959. sourceExperimental — accuracy not yet measured
The ‘Influence of extra-islet factors’ section says the glucagon response to hypoglycaemia can be deficient or absent in people with long-standing type 2 diabetes. This supports the duration-related point, but the passage addresses the glucagon response specifically, not the counter-regulatory response as a whole. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lack to timely treatment will then lead to Level 2 hypoglycemia (glucose below 3.0 mmol/L), also known as moderate hypoglycemia, when the person living with diabetes experiences neuroglycopenic symptoms such as confusion, drowsiness, slurred speech, and weakness [3–5].”
§ Systematic review of oral carbohydrate treatment for hypoglycemia in people living with type 2 diabetes mellitus > Introduction
What the sources say
- Not checked yetcites [3] Joint British Diabetes Societies for Inpatient Care. The hospital management of hypoglycaemia in adults with diabetes mellitus: JBDS-01 guideline January 2023. Available from: https://www.diabetes.org.uk/for-professionals/improving-care/good-practice/inpatient-and-hospital-care/joint-british-diabetes-society-for-inpatient-care
- Partly supportedcites [4] American Diabetes Association Professional Practice Committee. Glycemic goals and hypoglycemia: Standards of care in diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S128–S145. https://doi.org/10.2337/dc25-S006 . PMID: 39651981; PMCID: PMC11635034. sourceExperimental — accuracy not yet measured
The paper’s “Hypoglycemia Definitions and Event Rates” section defines level 2 as glucose below 3.0 mmol/L, where neuroglycopenic symptoms begin. “Hypoglycemia Treatment” advises treating at the level 1 alert threshold of 3.9 mmol/L or less. It does not say that failure to treat level 1 will necessarily lead to level 2. (LLM, conf=0.84)
- Partly supportedcites [5] Lega IC, Yale JF, Chadha A, Paty B, Roscoe R, Snider M, Steier J, et al. Diabetes Canada 2023 update clinical practice guidelines for the prevention and management of diabetes in Canada: hypoglycemia in adults. Can J Diabetes. 2023;47(7):548–559. https://guidelines.diabetes.ca/cpg/chapter-14-2023-update sourceExperimental — accuracy not yet measured
The Treatment of Hypoglycemia section says hypoglycemia should be treated immediately, and Table 2 classifies level 2 as glucose below 3.0 mmol/L with neuroglycopenic symptoms (page not provided). The paper does not say that failing to treat level 1 promptly will necessarily lead to level 2. (LLM, conf=0.83)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In people living with T2D, the counter-regulatory response to hypoglycemia, namely the secretion of glucagon and catecholamines, is often only mildly decreased, when compared with people living with T1D [1].”
§ Systematic review of oral carbohydrate treatment for hypoglycemia in people living with type 2 diabetes mellitus > Introduction
What the sources say
- Partly supportedcites [1] Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care. 2005;28(12):2948–2961. https://doi.org/10.2337/diacare.28.12.2948 . PMID: 16306561. sourceExperimental — accuracy not yet measured
In “The effects of type 2 diabetes on the responses to hypoglycemia” (page unavailable), the paper describes mostly mild hormonal deficiencies in type 2 diabetes, but says epinephrine secretion was preserved. It also reports that glucagon responses may be modestly diminished or preserved, and can be almost absent in insulin-deficient patients. The paper does not support describing both glucagon and catecholamine secretion as mildly decreased relative to people with type 1 diabetes; the type 1 comparison concerns the blood-glucose threshold at which hormones are released. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
19 more claims · 4 with their cited sources checked
Create a free account to see all 54 claims and to verify the 4 references still open.
- It may state two separate claims as one. 17
- Probably not a substantial claim. 16
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329 · cited 1×
“Compared to another commonly-used tool for risk-of-bias assessment (“Risk Of Bias In Non-randomised Studies - of Interventions” [24]), the Newcastle-Ottawa scale includes less detailed criteria for the evaluation of confounders, and protocol deviations.”
Haddaway, N. R., Page, M. J., Pritchard, C. C., & McGuinness, L. A. (2022) · Campbell Systematic Reviews · doi:10.1002/cl2.1230 · Cited by 3,486
Type 2 diabetes mellitus in older adults: clinical considerations and management
Bellary, S., Kyrou, I., Brown, J. E., & Bailey, C. J. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00512-2 · Cited by 639 · cited 1×
“Physiological symptoms due to hypoglycemia, and ability to self-treat both decline with increasing age [17, 22, 23].”
Phillip, M., Nimri, R., Bergenstal, R. M., Barnard-Kelly, K., Danne, T., Hovorka, R., Kovatchev, B. P., Messer, L. H., Parkin, C. G., Ambler-Osborn, L., et al. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac022 · Cited by 443
6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s006 · Cited by 440 · cited 1×
“With the increased use of continuous glucose monitors in people living with T2D, continuous glucose monitors could be integrated into future study designs for hypoglycemia treatment and personalized responses to various types and quantities of simple carbohydrate treatments [4].”
Hypoglycemia in Type 2 Diabetes
Zammitt, N. N., & Frier, B. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.12.2948 · Cited by 435
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.12.003 · Cited by 162
Signorovitch, J. E., Macaulay, D., Diener, M., Yan, Y., Wu, E. Q., Gruenberger, J. ‐., & Frier, B. M. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12031 · Cited by 125 · cited 1×
“Physiological symptoms due to hypoglycemia, and ability to self-treat both decline with increasing age [17, 22, 23].”
100 years of glucagon and 100 more
Wewer Albrechtsen, N. J., Holst, J. J., Cherrington, A. D., Finan, B., Gluud, L. L., Dean, E. D., Campbell, J. E., Bloom, S. R., Tan, T. M.-M., Knop, F. K., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-05947-y · Cited by 117
Research works printed but not linked: 1
- Dhatariya K, Corsino L, Umpierrez GE. Management of diabetes and hyperglycemia in hospitalized patients. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000‑. Updated 30 Dec 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279093/
Metadata
- Authors
- Prince, N., Lochnan, H., Shorr, R., Garon-Mailer, A., & Sun, C. J.
- Affiliations
- University of Ottawa (CA)
- Ottawa Hospital (CA)
- Corresponding author
- Sun, Cathy J.
- Venue
- BMC Endocrine Disorders
- Published
- 2026-01-22
- Volume
- 26
- Issue
- 1
- Pages
- 50-50
- ISSN
- 1472-6823 (ISSN-L)
- PMC
- PMC12895785
- OpenAlex
- W7125510268
- Semantic Scholar
- f20eff9c99a50bfd0a4fe57baf49691677b3e1a8
- Cited by
- 0
- References
- 26
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor, 21 d)
- Locations
- BMC Endocrine Disorders (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
- Keywords
- hypoglycemia, type 2 diabetes, monosaccharides, insulin-treated diabetes, sulfonylureas, rebound hyperglycemia, hospitalized patients, rapid-acting insulin
- MeSH terms
- Administration, Oral, Blood Glucose, Diabetes Mellitus, Type 2, Dietary Carbohydrates, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systematic review of oral carbohydrate treatment for hypoglycemia in people living with type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1186/s12902-025-02144-3
- The paper
- Prince, N., Lochnan, H., Shorr, R., Garon-Mailer, A., & Sun, C. J. (2026). Systematic review of oral carbohydrate treatment for hypoglycemia in people living with type 2 diabetes mellitus. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-025-02144-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
![Fig. 1 Literature search and screening flow diagram [9, 10]](https://figures.cochat.ai/paper-figures/aa6c7a32cc004c88b9c32be0fbc6e80d/systematic-review-of-oral-carbohydrate-treatment-for-hypoglycemia-in-people-figure-1.jpg)